Angelika Lackner, Teresa Burner, Marlene Brandner, Saptaswa Dey, Stefan Aigner, Veronika Buxhofer-Ausch, Marija Geroldinger-Simic, Christoph Iselin, Yun-Tsan Chang, Yi-Chien Tsai, Sabine Altrichter, Peter Wolf, Susanne Kimeswenger, Emmanuella Guenova, Wolfram Hoetzenecker
{"title":"Evidence of Immunogenic Cell Death (ICD) and ICD-dependent Dendritic Cell Activation Induced by Extracorporeal Photopheresis in Patients with leukemic forms of cutaneous T cell lymphoma.","authors":"Angelika Lackner, Teresa Burner, Marlene Brandner, Saptaswa Dey, Stefan Aigner, Veronika Buxhofer-Ausch, Marija Geroldinger-Simic, Christoph Iselin, Yun-Tsan Chang, Yi-Chien Tsai, Sabine Altrichter, Peter Wolf, Susanne Kimeswenger, Emmanuella Guenova, Wolfram Hoetzenecker","doi":"10.1093/bjd/ljaf102","DOIUrl":"https://doi.org/10.1093/bjd/ljaf102","url":null,"abstract":"<p><strong>Background: </strong>Despite novel therapeutic options, the long-term management of cutaneous T cell lymphoma (CTCL) remains challenging. Extracorporeal photopheresis (ECP) is an immunomodulating photochemotherapy associated with higher overall survival when used for the treatment of leukemic forms of CTCL. Its exact mode of action is not fully elucidated. Immunogenic cell death (ICD) is pivotal in cancer immunotherapy, marked by the release of damage-associated molecular patterns that enhance dendritic cell (DC) maturation and cytotoxic T lymphocyte responses.</p><p><strong>Objectives: </strong>This study explores ICD in patients with leukemic forms of CTCL during ECP and its effect on DC activation.</p><p><strong>Methods: </strong>We conducted in vitro studies with peripheral blood mononuclear cells (PBMCs) from healthy donors and ex vivo experiments with white blood cells (WBCs) from patients with leukemic forms of CTCL undergoing ECP. We assessed cell viability, apoptosis, and ICD markers (ATP, HMGB1, calreticulin) using flow cytometry, ELISA, and qPCR. Engulfment assays evaluated DC activation by ECP-treated CD4+ T cells.</p><p><strong>Results: </strong>ECP-treated healthy PBMCs and WBCs from patients with leukemic forms of CTCL showed significant induction of ICD hallmarks, including ATP release, HMGB1 secretion, and calreticulin surface exposure. In the patients with leukemic forms of CTCL, calreticulin expression was mainly present in CD4+CD26- T cells, indicating greater ICD susceptibility of malignant T cells. ECP-treated CD4+ T cells were phagocytosed by DCs, a process which we found to be dependent on ICD signals.</p><p><strong>Conclusions: </strong>ECP induces ICD in malignant T cells and, to a lesser extent, in healthy T cells, facilitating DC activation. These findings suggest that ECP enhances targeted immune responses against malignant T cells in leukemic forms of CTCL, offering new insights into its therapeutic mechanisms and potential applications in cancer immunotherapy.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chaw-Ning Lee, Miyuki Hsing-Chun Hsieh, Che-Yu Chen, Chao-Chun Yang, Tzu-Chi Liao, Edward Chia-Cheng Lai
{"title":"Risk of Herpes Zoster and Postherpetic Neuralgia in Patients with Psoriasis Treated with Biologics: A nationwide study using target trial emulation framework.","authors":"Chaw-Ning Lee, Miyuki Hsing-Chun Hsieh, Che-Yu Chen, Chao-Chun Yang, Tzu-Chi Liao, Edward Chia-Cheng Lai","doi":"10.1093/bjd/ljaf101","DOIUrl":"https://doi.org/10.1093/bjd/ljaf101","url":null,"abstract":"<p><strong>Background: </strong>Patients with psoriasis have a higher baseline risk of herpes zoster (HZ) than the general population. This has raised concerns that TNF-α inhibitor use may be associated with an increased risk of HZ. However, the risk profiles for newer biologics, including IL-17 inhibitor (IL-17i), IL-12/23 inhibitor (IL-12/23i) and IL-23 inhibitor (IL-23i), remain uncertain.</p><p><strong>Objective: </strong>To compare HZ and postherpetic neuralgia (PHN) risks among different biologics, including ustekinumab, secukinumab, ixekizumab, guselkumab, etanercept and adalimumab, with traditional systemic treatments (TST).</p><p><strong>Methods: </strong>We conducted a retrospective cohort study by analyzing data from Taiwan's National Health Insurance Research Database (NHIRD 2011-2021). We included patients with psoriasis or psoriatic arthritis aged 20 years and above who had been treated with biologics or TST for at least six months. We classified patients by individual biologics or TST and followed them up for 2.5 years from drug initiation until the occurrence of outcome events or death. The primary outcome was the diagnosis of HZ. We used inverse probability of treatment weighting (IPTW) to adjust for covariates, including patient age, sex, comorbidities and co-medications. We used Cox proportional hazards models to evaluate the risk of HZ among different biologics.</p><p><strong>Results: </strong>In total, we identified 815, 1870, 1095, 2327, 261, 303 and 98 patients with psoriasis receiving etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab and guselkumab, respectively. Compared to patients receiving TST, for those receiving ustekinumab and guselkumab the risk of HZ trended lower (weighted HR: 0.82, 95% CI: 0.61-1.11; 0.48, 0.22-1.02), while for those receiving adalimumab it was statistically significantly higher (weighted HR: 1.63, 95% CI: 1.22-2.18). Additionally, ustekinumab was associated with a reduced risk of PHN (HR: 0.22, 95% CI: 0.08-0.64). There were no significant differences in the risk of HZ between TST and either etanercept, secukinumab, ixekizumab or brodalumab.</p><p><strong>Conclusions: </strong>The findings suggested ustekinumab and guselkumab may be associated with a reduced risk of HZ and PHN, compared to TST. This study could have significance for real-world practice.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Javier de la Iglesia Martin, Jessica Martin Vera, Carla Tubau Prims
{"title":"Dermatitis cruris pustulosa et atrophicans.","authors":"Javier de la Iglesia Martin, Jessica Martin Vera, Carla Tubau Prims","doi":"10.1093/bjd/ljaf103","DOIUrl":"https://doi.org/10.1093/bjd/ljaf103","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Megan H Trager, Emily R Gordon, Alyssa Breneman, Annie Brito, Olivia Vivadelli, Jenna Wenzel, Tatyana R Humphreys, Juliya Fisher, Courtney Ensslin, Faramarz H Samie
{"title":"Diagnosis and Management of Mohs Surgery Complications by Large Language Models Using Pre-Constructed Written Scenarios.","authors":"Megan H Trager, Emily R Gordon, Alyssa Breneman, Annie Brito, Olivia Vivadelli, Jenna Wenzel, Tatyana R Humphreys, Juliya Fisher, Courtney Ensslin, Faramarz H Samie","doi":"10.1093/bjd/ljaf100","DOIUrl":"https://doi.org/10.1093/bjd/ljaf100","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eli Sprecher, Akemi Ishida-Yamamoto, Janice Schwartz, Masashi Akiyama, Mandy Aldwin-Easton, Keith Choate, Judith Fischer, Antoni Gostyński, Céline Granier Tournier, Angela Hernandez-Martin, Alain Hovnanian, Kiril Malovitski, Juliette Mazereeuw-Hautier, Amy S Paller, Matthias Schmuth, Gianluca Tadini, Joyce Teng, Christine Bodemer, Edel A O'Toole
{"title":"Palmoplantar epidermal differentiation disorders: a new classification towards pathogenesis-based therapy.","authors":"Eli Sprecher, Akemi Ishida-Yamamoto, Janice Schwartz, Masashi Akiyama, Mandy Aldwin-Easton, Keith Choate, Judith Fischer, Antoni Gostyński, Céline Granier Tournier, Angela Hernandez-Martin, Alain Hovnanian, Kiril Malovitski, Juliette Mazereeuw-Hautier, Amy S Paller, Matthias Schmuth, Gianluca Tadini, Joyce Teng, Christine Bodemer, Edel A O'Toole","doi":"10.1093/bjd/ljaf054","DOIUrl":"https://doi.org/10.1093/bjd/ljaf054","url":null,"abstract":"<p><p>More than 50 palmoplantar epidermal differentiation disorders (pEDDs) have been reported in the literature. Various descriptors have been used to name these conditions including clinical features often designated as acronyms or evocative terms, names of clinicians and of geographical locations. Not only has this nomenclature been criticized for its lack of methodological consistency, it has progressively lost its clinical relevance. Indeed, the advent of a wide range of pathogenesis-targeting therapeutic solutions for these disorders has raised the need for a novel classification of pEDDs, based on their causative genetic defects, to provide clinicians with genuine therapeutic guidance. Here, we present a novel classification scheme for pEDDs and its application in the form of a practical algorithm for the rapid diagnosis of pEDDs.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study.","authors":"Cheng-Yuan Li, Wei-Ting Wang, Sheng-Hsiang Ma, Li-Wei Lo, Chen-Yi Wu, Wei-Chuan Chang, Yi-Ju Chen, Tai-Li Chen","doi":"10.1093/bjd/ljae438","DOIUrl":"10.1093/bjd/ljae438","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence has shown that cholesterol metabolism abnormalities involve carcinogenesis. Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors have been reported to inhibit tumour progression and prevent ultraviolet-related skin damage.</p><p><strong>Objectives: </strong>To investigate the association of PCSK9 inhibitors with the risk of nonmelanoma skin cancer (NMSC).</p><p><strong>Methods: </strong>This retrospective cohort study analysed data from the US Collaborative Network in the TriNetX database. Adults aged ≥ 40 years with atherosclerotic cardiovascular disease (ASCVD) under statin therapy between 2016 and 2022 were identified. A target trial design was used to compare the risk of NMSC, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), in patients also treated with PCSK9 inhibitors or continuing statin treatment (the control group). Each head-to-head comparison involved propensity score matching. Hazard ratios (HRs) were estimated using Cox proportional hazard models. Stratified analyses based on age, sex, Fitzpatrick skin type and immune status were also performed.</p><p><strong>Results: </strong>A total of 73 636 patients with ASCVD were analysed. Compared with the control group, patients with ASCVD initiating PCSK9 inhibitors had lower risks of developing NMSC [HR 0.78, 95% confidence interval (CI) 0.71-0.87], BCC (HR 0.78, 95% CI 0.69-0.89) and cSCC (HR 0.79, 95% CI 0.67-0.93). Subanalyses revealed a reduced risk of NMSC with each PCSK9 inhibitor, namely evolocumab and alirocumab. Stratified analyses showed similar results in patients aged 65-79 years, those older than 80 years and in men.</p><p><strong>Conclusions: </strong>Our study indicated that patients with ASCVD taking PCSK9 inhibitors have a lower risk of incident NMSC than those not taking PCSK9 inhibitors.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"697-705"},"PeriodicalIF":11.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Serpiginous pustules and erythematous plaques on the soles of the feet.","authors":"Tian Chen, Dong-Lai Ma","doi":"10.1093/bjd/ljae497","DOIUrl":"10.1093/bjd/ljae497","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"776"},"PeriodicalIF":11.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}